Updates in endocrine therapy for metastatic breast cancer

Endocrine therapy (ET) remains the mainstay of treatment for steroid hormone receptor-positive, human epidermal growth factor 2 (HER2)-negative metastatic breast cancer (MBC). Tumor resistance to hormone therapy has led to the development of novel endocrine drug combinations, transforming the landsc...

Descripción completa

Detalles Bibliográficos
Autores principales: Manohar, Poorni M., Davidson, Nancy E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832960/
https://www.ncbi.nlm.nih.gov/pubmed/34609096
http://dx.doi.org/10.20892/j.issn.2095-3941.2021.0255

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832960/
https://www.ncbi.nlm.nih.gov/pubmed/34609096
http://dx.doi.org/10.20892/j.issn.2095-3941.2021.0255

Ejemplares similares